Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC), a type of liver cancer, remains a treatment challenge due to late detection and resistance to currently approved drugs. It takes 15–20 years for a single new drug to become FDA approved. The purpose of this study was to expedite identification of novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Regan-Fendt, Kelly, Li, Ding, Reyes, Ryan, Yu, Lianbo, Wani, Nissar A., Hu, Peng, Jacob, Samson T., Ghoshal, Kalpana, Payne, Philip R.O., Motiwala, Tasneem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598246/
https://www.ncbi.nlm.nih.gov/pubmed/32977582
http://dx.doi.org/10.3390/cancers12102730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598246/
https://www.ncbi.nlm.nih.gov/pubmed/32977582
http://dx.doi.org/10.3390/cancers12102730

Ejemplares similares